Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, …
Over the last 12 months, insiders at Medpace Holdings, Inc. have bought $0 and sold $765.4M worth of Medpace Holdings, Inc. stock.
On average, over the past 5 years, insiders at Medpace Holdings, Inc. have bought $260.16M and sold $450.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 57,426 shares for transaction amount of $8.88M was made by Troendle August J. (CEO) on 2022‑09‑22.
2024-08-23 | Sale | director | 3,774 0.0122% | $390.73 | $1.47M | -11.76% | ||
2024-06-05 | Sale | Exec. VP, Operations | 7,681 0.0244% | $401.20 | $3.08M | -13.17% | ||
2024-05-28 | Sale | CEO | 5,695 0.0186% | $395.49 | $2.25M | -8.87% | ||
2024-05-24 | Sale | CEO | 3,987 0.013% | $395.22 | $1.58M | -8.67% | ||
2024-05-22 | Sale | CEO | 55 0.0002% | $400.00 | $22,000 | -8.03% | ||
2024-05-20 | Sale | CEO | 4,020 0.0131% | $400.19 | $1.61M | -9.17% | ||
2024-05-16 | Sale | CEO | 7,060 0.0229% | $403.09 | $2.85M | -8.03% | ||
2024-05-15 | Sale | CEO | 32,282 0.104% | $405.13 | $13.08M | -10.97% | ||
2024-05-10 | Sale | CEO | 4,956 0.0165% | $402.89 | $2M | -7.28% | ||
2024-05-09 | Sale | CEO | 3,486 0.0113% | $400.17 | $1.39M | -9.26% | ||
2024-05-08 | Sale | CEO | 4,782 0.016% | $400.58 | $1.92M | -6.40% | ||
2024-05-07 | Sale | CEO | 28,032 0.0913% | $404.48 | $11.34M | -9.68% | ||
2024-05-06 | Sale | CEO | 24,372 0.0789% | $401.73 | $9.79M | -9.27% | ||
2024-05-02 | Sale | CEO | 3,396 0.0112% | $400.44 | $1.36M | -6.49% | ||
2024-05-01 | Sale | CEO | 12,934 0.0421% | $401.56 | $5.19M | -8.05% | ||
2024-04-30 | Sale | CEO | 1,828 0.0061% | $400.31 | $731,767 | -5.77% | ||
2024-04-29 | Sale | CEO | 15,102 0.0488% | $400.69 | $6.05M | -8.32% | ||
2024-03-15 | Sale | Exec. VP, Operations | 102 0.0003% | $403.00 | $41,106 | -3.16% | ||
2024-03-14 | Sale | director | 250 0.0008% | $409.87 | $102,468 | -4.85% | ||
2024-03-08 | Sale | CEO | 25,000 0.0818% | $408.71 | $10.22M | -5.07% |
Medpace Investors, LLC | 10 percent owner | 4733019 15.2277% | $342.69 | 14 | 178 | +37.55% |
Troendle August J. | CEO | 654656 2.1062% | $342.69 | 16 | 197 | +33.41% |
BURWIG SUSAN E | Exec. VP, Operations | 7500 0.0241% | $342.69 | 2 | 10 | +3.69% |
DAVENPORT FRED B JR | director | 2000 0.0064% | $342.69 | 1 | 0 | +12.85% |
The Vanguard Group | $1.01B | 8.08 | 2.5M | -2.04% | -$21.07M | 0.02 | |
BlackRock | $1.01B | 8.05 | 2.49M | +3.1% | +$30.28M | 0.02 | |
Wasatch Advisors | $393.81M | 3.15 | 974,415 | -17.85% | -$85.59M | 2.06 | |
Invesco | $329.71M | 2.63 | 815,801 | +12.8% | +$37.41M | 0.07 | |
State Street | $281.68M | 2.25 | 696,959 | +3.85% | +$10.43M | 0.01 |